Therapies

Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track

19 days ago   |   By Xconomy

Solid Biosciences is slashing its workforce, including two top executives, in order to devote the company's remaining resources to its experimental gene therapy for Duchenne muscular dystrophy. The corporate restructuring announced Thursday comes two months after the FDA placed a hold on the study after safety problems emerged that were linked to the gene therapy, SGT-001. Cambridge, MA-based Solid Bio says going forward it will focus on how to address the clinical hold and resume testing. With the corporate changes, Solid Bio says it has enough cash to last into next year. At the end of...
Read more ...

 


Search by Tags

   Therapies      Biosciences      Clinical      Gene      Genes      Gene Therapy      Boston      Boston blog main      Boston top stories      National blog main      National top stories      Alvaro Amorrortu      Biotech      Clinical trials      Duchenne Muscular Dystrophy      FDA      Jorge Quiroz      Life Sciences      Solid Biosciences  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie

Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie

Allergan is selling off an experimental drug and a commercialized product in order to allay antitrust concerns from regulators reviewing the company's $63 billion acquisition... Read more ...

Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets

Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets

Two privately held biotechs on Tuesday announced plans for reverse mergers, transactions that provide a faster route to go public than a conventional IPO and also give... Read more ...

Third Time's the Charm as Acceleron Drug Shows Early Promise in PAH

Third Time's the Charm as Acceleron Drug Shows Early Promise in PAH

Sotatercept was one of the first compounds to emerge from the labs of Acceleron Pharma, but it became a forgotten piece of the company's pipeline. Passed over as a candidate to... Read more ...

BioIntelliSense Debuts ”Sticker” Sensor to Capture Patient Data Remotely

BioIntelliSense Debuts ”Sticker” Sensor to Capture Patient Data Remotely

Subtle changes can presage a worsening of a chronic condition, but symptoms may not become apparent to a patient until it's time to call an ambulance. BioIntelliSense, a... Read more ...

Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report

Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report

Biopharmaceutical companies focused on advanced therapies are changing industry R&D, manufacturing, and supply chain models according to KPMG. The audit, tax, and advisory... Read more ...

Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family

Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family

About 7 million couples in the US have difficulty getting or staying pregnant. A new biotech is using insights into the biology of male reproductive cells-the sperm that must... Read more ...

Quench Bio Springs From Atlas With $50M for a New Take on Inflammation

Quench Bio Springs From Atlas With $50M for a New Take on Inflammation

Cells die all the time in a controlled manner that's perfectly normal. But the way cells die matters. Sometimes cell death is violent, sparking inflammation believed to... Read more ...

When Snakes Strike: SMRT Sequencing Reveals Hidden “Venom-ome”

When Snakes Strike: SMRT Sequencing Reveals Hidden “Venom-ome”

A team of scientists from SciGenom Research Foundation in India has assembled the genome and transcriptome of the lethal Indian Cobra using PacBio long-read sequencing Snake... Read more ...

Life Sciences IPOs Target Collective Raise of More Than $600M This Week

Life Sciences IPOs Target Collective Raise of More Than $600M This Week

So far this year four privately held companies have made the transition to trading on the public markets. By month's end, five more are anticipated to join the class of 2020... Read more ...

Youth and Educators Pledge to Support Biotech Application in Uganda

Over the past six years, Uganda Biosciences Information Center has registered remarkable progress in cultivating a positive perception of recent advances in science among the... Read more ...